Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Applied Therapeutics, Inc. - Common Stock (NQ:APLT)

0.5335 +0.0190 (+3.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Applied Therapeutics, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Applied Therapeutics Reports Second Quarter 2024 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock Upside
William Blair has initiated coverage on Applied Therapeutics highlighting its focus on rare diseases such as galactosemia, SORD deficiency, and diabetic cardiomyopathy. With govorestat (AT-007) poised... 
Via Benzinga
CrossFirst Bankshares Posts Q2 Earnings, Joins Owens & Minor, Reddit And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Applied Therapeutics Added to Russell 3000® Index
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics: Q4 Earnings Insights
 
Via Benzinga
Top 4 Health Care Stocks That May Keep You Up At Night This Month
 
Via Benzinga
APLT Stock Earnings: Applied Therapeutics Meets EPS, Misses Revenue for Q1 2024
APLT stock results show that Applied Therapeutics met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Applied Therapeutics Reports First Quarter 2024 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024
From Applied Therapeutics
Via GlobeNewswire
FDA Presses Delay Button For Applied Therapeutics' First Potential Marketed Drug For Rare Disease
FDA extends the review period for Applied Therapeutics' NDA for govorestat, targeting Classic Galactosemia treatment. The new action date is set for November 28, 2024. Applied Therapeutics anticipates... 
Via Benzinga
Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket
Shares of Doma Holdings Inc. (NYSE: DOMA) rose sharply in today’s pre-market trading after the company entered a merger transaction with TRG to go private at $6.29 per share in cash. Doma Holdings... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Oxford Industries Posts Weak Results, Joins Applied Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining by over 100 points on Monday. 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
From Applied Therapeutics
Via GlobeNewswire
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday. 
Via Benzinga
Topics Stocks
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results. 
Via Benzinga
Advance Auto Parts Reports Q4 Results, Joins B&G Foods, Vipshop, ADT And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Wednesday. 
Via Benzinga
Topics Stocks
FDA Grants Review Date For Applied Therapeutics' First Commercial Product For Rare Metabolic Disorder
Applied Therapeutics surges as FDA grants Priority Review to govorestat (AT-007) for Galactosemia treatment. If approved, it would be the first medication for Galactosemia. APLT also submits MAA to... 
Via Benzinga
Why Is Coupang (CPNG) Stock Up 4% Today?
Coupang stock is rallying on Wednesday as investors in CPNG celebrate the company beating out EPS and revenue estimates for Q4. 
Via InvestorPlace
Applied Therapeutics Inc. (NASDAQ: APLT) Records 52-Week High Wednesday Morning
Via Investor Brand Network
Why Is Applied Therapeutics (APLT) Stock Up 59% Today?
Applied Therapeutics stock is rising higher on Wednesday alongside heavy trading of APLT following an update from the FDA. 
Via InvestorPlace
Applied Therapeutics Announces $100 Million Private Placement
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
From Applied Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Why Is Rare Disease-Focused Applied Therapeutics Stock Trading Higher Today?
Results of Applied Therapeutics' Phase 3 INSPIRE trial for oral govorestat (AT-007). Govorestat demonstrates significant sorbitol reduction, improving mobility and overall well-being in SORD Deficiency... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.